In this large study of >3500 population-representative primary breast cancers profiled by RNA sequencing, it was observed that essentially all subtypes are represented, albeit often in small proportions, in clinical treatment groups defined by the combination of ER, PR, and HER2 status and the administered therapy. This evidence concerns the gene ESR1 and breast carcinoma.